10x Genomics, Inc., a Pleasonton, Calif.-based company that build products combining hardware, chemistry, and software to give single cell and spatial views of biological systems, priced its initial public offering.
Its Class A common stock are offered at a price of $39.00 per share, before underwriting discounts and commissions.
10x Genomics is offering 10,000,000 shares of its Class A common stock, plus up to an additional 1,500,000 shares of its Class A common stock that the underwriters have the right to purchase at the initial public offering price, less the underwriting discounts and commissions.
The shares are expected to begin trading on the Nasdaq Global Select Market on September 12, 2019 under the symbol “TXG” and the offering is expected to close on September 16, 2019, subject to the satisfaction of customary closing conditions.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and BofA Merrill Lynch are acting as lead joint book-running managers for the offering. Cowen is acting as lead manager for the offering.
10X is building DNA sequencing technology
FinSMEs
12/09/2019